Enclomiphene Citrate Cost in Hawaii 2026

What Is Enclomiphene Citrate and Why Does It Matter for Men in Hawaii?

Enclomiphene citrate is the trans-stereoisomer of clomiphene citrate. It acts as a selective estrogen receptor modulator (SERM) at the hypothalamus, blocking negative estrogen feedback and raising endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH) output, which in turn drives the testes to produce more testosterone. Unlike exogenous testosterone replacement therapy (TRT), enclomiphene preserves the hypothalamic-pituitary-gonadal (HPG) axis and maintains sperm production, making it attractive for men who want to address low testosterone without compromising fertility.

Secondary hypogonadism, the condition enclomiphene targets, is more common than many clinicians expect. The Endocrine Society estimates that symptomatic androgen deficiency affects roughly 2 to 6 percent of men overall, with prevalence rising steeply after age 40 [1]. In Hawaii, where the male population includes a high proportion of military veterans and active-duty personnel, rates of hypogonadism-related complaints at men's health clinics are consistent with national figures.

Kim et al. (BJU Int, 2016, N=310) demonstrated that enclomiphene 12.5 mg and 25 mg daily raised serum testosterone from a mean baseline of 230 ng/dL to above 400 ng/dL while maintaining sperm concentrations, compared with a decline in sperm concentration observed in the testosterone gel arm [2]. That preservation of sperm output is one of the key clinical reasons practitioners choose enclomiphene over topical or injectable testosterone for younger men.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states: "In men with hypogonadotropic hypogonadism who wish to maintain fertility, we suggest treatment with gonadotropins or clomiphene citrate rather than testosterone" [1]. Enclomiphene, as the purified trans-isomer, is increasingly preferred over racemic clomiphene for this indication.

How Much Does Enclomiphene Citrate Cost in Hawaii in 2026?

The cash price for compounded enclomiphene citrate in Hawaii runs approximately $90 per month through a licensed 503A compounding pharmacy in 2026. That figure covers a 30-day supply of oral capsules or tablets at doses between 12.5 mg and 25 mg daily.

There is no FDA-approved branded enclomiphene product currently on the U.S. market. Androxal (enclomiphene citrate, Repros Therapeutics) completed Phase III trials but was not approved by the FDA [3]. Without a commercially manufactured reference drug, patients and prescribers rely entirely on the compounding pathway, which is where the $90/month figure originates.

Compounded drug pricing varies by pharmacy, quantity dispensed, and capsule strength. A 25 mg capsule formulation may cost modestly more than a 12.5 mg formulation at certain pharmacies because of raw-material quantities. Some telehealth platforms bundle the prescriber consultation fee into a monthly subscription that may bring all-in costs to $120 to $180 per month when the visit fee is included. The pharmacy dispensing fee alone, however, sits near $90 for most licensed 503A pharmacies serving Hawaiian patients.

For comparison, the wholesale cost of testosterone cypionate 200 mg/mL (10 mL vial) is approximately $30 to $50 per vial at compounding pharmacies, with a monthly injectable dose costing around $40 to $60 [4]. Enclomiphene is therefore somewhat more expensive than basic injectable TRT but substantially less costly than branded testosterone products, which can run $300 to $500 per month without insurance.

Is Enclomiphene Citrate Covered by Hawaii Medicaid?

Hawaii Medicaid (Med-QUEST) does not cover enclomiphene citrate for secondary hypogonadism in 2026. The off-label status of the drug for this indication is the primary barrier. Med-QUEST managed care plans follow formulary decisions tied to FDA-approved indications, and because no branded enclomiphene product holds FDA approval, there is no NDC code to submit for reimbursement [5].

Patients on Med-QUEST who need treatment for secondary hypogonadism may find that racemic clomiphene citrate (Clomid, generic) is occasionally covered, because clomiphene holds FDA approval for ovulation induction and has an established generic market. Some prescribers use generic clomiphene off-label in men, though the zuclomiphene isomer in the racemic mix may cause more estrogenic side effects than the pure enclomiphene trans-isomer [2].

Appealing a Med-QUEST denial for enclomiphene is possible but has a low success rate given the absence of FDA approval for this specific molecule in men. The Endocrine Society's 2018 guideline [1] and supporting trial data from Kim et al. [2] can be submitted as part of a medical necessity appeal, but patients should expect a denial and plan accordingly. The compounding pharmacy cash-pay route at $90/month is the most practical option for Med-QUEST enrollees in Hawaii.

Does Commercial Insurance Cover Enclomiphene Citrate in Hawaii?

Most commercial insurance plans sold in Hawaii, including HMSA (Hawaii Medical Service Association), Kaiser Permanente Hawaii, and AlohaCare, exclude compounded drugs from formulary coverage by default. Compounded medications lack FDA-approved labeling and an NDC, which are prerequisites for standard pharmacy benefit adjudication [5].

Even when a plan technically allows compounded drug claims, enclomiphene faces a second barrier: the off-label indication. Insurers frequently cite the lack of an approved indication when denying prior authorization. An analysis of SERM use in men published in the Journal of Urology found that insurance denial rates for clomiphene-class drugs in male hypogonadism exceeded 70 percent across commercial payers [6].

Prior authorization attempts citing the Endocrine Society guideline [1] and the Kim et al. trial [2] occasionally succeed at plans with liberal formulary exception processes. Patients who have documented testosterone levels below 300 ng/dL on two morning fasting samples, combined with symptoms of hypogonadism and a confirmed low or inappropriately normal LH, have the strongest case for medical necessity. An FSH level above the lower limit of normal also supports the secondary rather than primary hypogonadism diagnosis, which strengthens the rationale for a SERM over exogenous testosterone [1].

In practice, fewer than 15 to 20 percent of patients in Hawaii who pursue insurance coverage for enclomiphene succeed on the first or second appeal. Most transition to cash-pay compounding within 30 to 60 days of starting the appeal process.

Is Compounded Enclomiphene Citrate Legal in Hawaii?

Yes. Compounded enclomiphene citrate is legal in Hawaii when dispensed by a pharmacy licensed under Section 503A of the Federal Food, Drug, and Cosmetic Act. A 503A pharmacy compounds drugs for individual patients based on a valid prescription from a licensed practitioner [7].

Hawaii follows federal 503A rules. The Hawaii Board of Pharmacy licenses and inspects compounding pharmacies operating within the state. Out-of-state 503A pharmacies may also ship compounded enclomiphene to Hawaii patients as long as the out-of-state pharmacy holds a Hawaii non-resident pharmacy permit and the prescription is valid [8].

Section 503B outsourcing facilities (which produce large-batch compounded drugs without patient-specific prescriptions) are not legally permitted to compound enclomiphene for office-stock distribution in Hawaii unless the drug meets specific shortage criteria, which enclomiphene currently does not [7]. This means every legitimate dispensing of compounded enclomiphene in Hawaii must flow through the 503A pathway, anchored to an individual patient prescription.

The FDA's guidance on compounding from bulk drug substances identifies enclomiphene citrate as a substance that may be compounded under 503A, provided it meets U.S. Pharmacopeia (USP) or National Formulary (NF) standards for the active pharmaceutical ingredient [7]. Patients should confirm that the compounding pharmacy uses a certificate of analysis (COA) from a reputable API supplier and conducts potency testing.

Can Patients in Hawaii Get Enclomiphene via Telehealth?

Telehealth prescribing of enclomiphene citrate is fully legal in Hawaii. The state's telehealth parity law (Hawaii Revised Statutes Chapter 431M) requires that services covered for in-person care may also be delivered via telehealth, and the Hawaii Medical Board permits prescribing of controlled and non-controlled medications via synchronous audio-video encounters after a valid patient-provider relationship is established [9].

Enclomiphene is not a controlled substance, which removes the additional Ryan Haight Act constraints that apply to, for example, testosterone injectable preparations or Schedule III compounds. A licensed physician or advanced practice registered nurse (APRN) in Hawaii can evaluate a patient via video call, review lab results, and issue a valid prescription for compounded enclomiphene without an in-person visit.

The typical telehealth workflow for enclomiphene in Hawaii runs as follows. The patient completes an intake form, submits recent labs (total testosterone, LH, FSH, comprehensive metabolic panel), and schedules a video consultation. The provider reviews labs and symptoms, confirms the secondary hypogonadism diagnosis, and sends the prescription electronically to a licensed 503A compounding pharmacy. Follow-up visits every 90 days are standard to reassess testosterone levels and symptoms. Total time from first contact to prescription arrival is often 3 to 5 business days.

Patients on neighbor islands (Maui, Kauai, Hawaii Island, Molokai, Lanai) benefit disproportionately from this model, given limited access to endocrinology or urology specialists outside Honolulu. A 2022 review in Telemedicine and e-Health found that rural and island-based patients reported equivalent satisfaction and clinical outcomes from telehealth-based hormone management compared with in-person care [10].

What Labs Are Required Before Starting Enclomiphene in Hawaii?

Before a Hawaii telehealth provider or in-person clinician prescribes enclomiphene, a minimum laboratory panel is required. The Endocrine Society's 2018 guideline [1] recommends confirming low testosterone on at least two morning fasting measurements (drawn before 10 a.m.) with simultaneous LH and FSH to distinguish primary from secondary hypogonadism.

A standard pre-treatment panel includes:

• Total testosterone (two separate morning draws, fasting)
• LH and FSH (to confirm secondary rather than primary hypogonadism)
• Sex hormone-binding globulin (SHBG) and calculated free testosterone
• Prolactin (to exclude a pituitary adenoma as the cause of low LH)
• Complete blood count (CBC) with hematocrit
• Comprehensive metabolic panel (CMP)
• Lipid panel

Elevated prolactin above 30 ng/mL warrants pituitary MRI before starting any SERM, because a macroadenoma requires direct treatment rather than downstream HPG axis stimulation [1]. Testicular ultrasound may be added if physical exam reveals asymmetry or a mass.

Follow-up labs at 6 to 8 weeks after starting enclomiphene typically include total testosterone, LH, FSH, estradiol, and hematocrit. If testosterone has not risen above 400 ng/dL and symptoms persist, the dose may be titrated from 12.5 mg to 25 mg daily. Kim et al. showed that the 25 mg daily dose achieved a mean testosterone of 481 ng/dL at 3 months versus 328 ng/dL with placebo (P<0.001) [2].

How Does Enclomiphene Compare with Clomiphene and TRT for Hawaiian Men?

The three main options for secondary hypogonadism in men are racemic clomiphene citrate (generic Clomid), enclomiphene citrate, and exogenous TRT (injectable testosterone cypionate, topical gels, or pellets). Each has a distinct cost and clinical profile in the Hawaii market.

Generic clomiphene citrate 25 to 50 mg every other day costs approximately $15 to $30 per month at standard retail pharmacies in Hawaii and may carry insurance coverage under the generic clomiphene NDC. The downside is the zuclomiphene isomer, which has a half-life of 30 days and accumulates with repeated dosing, potentially driving estradiol up and causing gynecomastia, mood changes, or visual disturbances [2]. Enclomiphene avoids this because it contains only the trans-isomer.

Injectable testosterone cypionate 200 mg every 2 weeks costs $40 to $60 per month through compounding or $150 to $300 through branded options. It is highly effective at raising testosterone, but suppresses LH to near zero within weeks, rendering the patient functionally infertile during treatment. Testicular volume typically decreases by 20 to 30 percent over 12 months of TRT [11]. For men in Hawaii under age 40 who are considering future fertility, this is a significant concern.

Enclomiphene at $90/month occupies the middle ground: it costs more than generic clomiphene but delivers a cleaner pharmacological profile, and it costs less than most branded TRT products while preserving fertility. A meta-analysis of SERMs in male hypogonadism published in Andrology (2022) found that clomiphene-class agents increased total testosterone by a mean of 200 to 300 ng/dL from baseline without significant suppression of sperm parameters [12].

The HealthRX clinical team uses a structured decision framework for Hawaii patients choosing between these options. Men with a total testosterone below 300 ng/dL on two morning draws, confirmed secondary hypogonadism (low-normal LH), age below 45, and active or future fertility interest are offered enclomiphene as a first-line oral option before TRT is considered. Men above 45 with no fertility concerns and testosterone below 200 ng/dL are typically moved to TRT more quickly.

What Is the Cheapest Way to Get Enclomiphene Citrate in Hawaii?

At $90/month through a licensed 503A compounding pharmacy, compounded enclomiphene is already the lowest-cost legitimate route. Several strategies may reduce the effective monthly cost further.

First, telehealth platforms that include the consultation fee in a flat monthly subscription (typically $120 to $180 all-in) may be cheaper than paying separately for an in-person endocrinology visit ($250 to $400 per visit in Honolulu) plus pharmacy costs. The telehealth model bundles everything and ships the medication directly to the patient's Hawaii address.

Second, some compounding pharmacies offer a 90-day supply discount. A three-month supply paid upfront may cost $240 to $250 rather than $270 (three months at $90), a modest but real saving.

Third, manufacturer or pharmacy savings cards do not apply to compounded drugs because there is no branded product sponsoring a copay card. GoodRx and similar platforms also do not list compounded enclomiphene because it lacks an NDC. Patients should be cautious of any third-party "discount program" that claims to apply a copay card to a compounded drug, as this may violate Anti-Kickback Statute safe harbors [13].

Fourth, if a provider is willing to trial generic clomiphene citrate first and the patient tolerates it without excess estrogenic side effects, that $15 to $30/month option should be considered as a diagnostic and therapeutic first step, with enclomiphene as an upgrade if clomiphene is not tolerated [6].

Are There Hawaii-Specific Discount or Assistance Programs?

No state-sponsored pharmaceutical assistance program in Hawaii covers compounded enclomiphene citrate as of mid-2025. The Hawaii Rx Plus program assists elderly and disabled residents with branded drug costs but does not extend to compounded preparations [14].

NeedyMeds and RxAssist, two national patient assistance databases, do not list enclomiphene among their covered drugs because no pharmaceutical manufacturer currently produces an FDA-approved branded product. The Hawaii Department of Health's pharmaceutical assistance resources are similarly limited to listed formulary drugs [14].

The most effective cost-reduction strategy available to Hawaii patients remains the telehealth-plus-503A-compounding model at $90/month, combined with a 90-day supply discount where available.

Clinical Safety Considerations Before Starting Enclomiphene in Hawaii

Enclomiphene is generally well tolerated. The most common adverse effects in Kim et al.'s Phase III data included hot flashes (reported in 12.5% of the enclomiphene 25 mg group versus 2% placebo), headache, and mild gastrointestinal discomfort [2]. Visual changes, a concern with high-dose racemic clomiphene, have been reported less frequently with enclomiphene because the zuclomiphene isomer is absent [2].

Estradiol monitoring is important. Because enclomiphene raises endogenous testosterone, aromatization to estradiol also increases. If estradiol climbs above 40 to 50 pg/mL and the patient reports nipple sensitivity or mood changes, the dose may need reduction or an aromatase inhibitor may be considered, though routine aromatase inhibitor co-prescription is not recommended by the Endocrine Society [1].

Men with a history of thromboembolic events should discuss risks with their provider before starting any SERM, as estrogen receptor modulation carries a theoretically elevated venous thromboembolism risk, though this has not been demonstrated at the doses used in male hypogonadism trials [2]. The FDA's MedWatch system allows patients and providers to report adverse events from compounded enclomiphene [15].

A 2021 review in Translational Andrology and Urology summarized the safety profile across available SERM trials in men: "Selective estrogen receptor modulators represent a reasonable, fertility-preserving alternative to testosterone therapy in carefully selected men with secondary hypogonadism, with an acceptable adverse-effect profile at doses used clinically" [16].